C07K 14/19
Rubella virus
C07K14/19 (Rubella virus) appears on 2 US grants and 5 published applications in this corpus.
Search patents in C07K- Granted patents
- 2
- Published applications
- 5
- Assignees
- 3
- Inventors
- 5
- Latest grant
- 25 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 1 | 0 |
| 2024 | 0 | 2 |
| 2025 | 1 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins25 Feb 2025US 12,233,119 B2Prime Bio, Inc.
- Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins3 Oct 2023US 11,771,752 B2Prime Bio, Inc.
- Vaccine antigens and use thereof29 Jan 2026US 2026/0027197 A1Morehouse School of Medicine
- Composition for Oral or Nasal Delivery of Tetanus, Diphtheria, and Pertussis Vaccine alone or in combination using Neurotoxin Associated Proteins11 Jul 2024US 2024/0226262 A9Prime Bio, Inc.
- Composition for Oral or Nasal Delivery of Tetanus, Diphtheria, and Pertussis Vaccine alone or in combination using Neurotoxin Associated Proteins25 Apr 2024US 2024/0131137 A1Prime Bio, Inc.
- Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type27 Jan 2022US 2022/0023401 A1United Biomedical, Inc.
- Composition for Oral or Nasal Delivery of Tetanus, Diphtheria, and Pertussis Vaccine alone or in combination using Neurotoxin Associated Proteins14 Mar 2019US 2019/0076518 A1Prime Bio, Inc.
Most cited
By later US patents